

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BIOSYSEN LIMITED

生物系統工程有限公司

*(formerly known as “Legend Strategy International Holdings Group Company Limited
枋濬國際集團控股有限公司”)*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1355)

PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL

The board (the “**Board**”) of directors (the “**Director(s)**”) of Biosysen Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) proposes to increase the authorised share capital of the Company from HK\$20,000,000 divided into 2,000,000,000 shares of the Company of HK\$0.01 each (the “**Shares**”) to HK\$100,000,000 divided into 10,000,000,000 Shares by the creation of an additional 8,000,000,000 Shares which, if issued, shall rank *pari passu* in all respects with the existing Shares (the “**Increase in Authorised Share Capital**”).

As at the date of this announcement, 1,193,065,160 Shares are in issue and 806,934,840 Shares are authorised but unissued. In order to accommodate the potential growth and development of the Group and to provide the Company with greater flexibility to raise funds in the future, the Board believes the Increase in Authorised Share Capital is in the interests of the Company and its shareholders (the “**Shareholders**”) as a whole.

Save for (i) the proposed rights issue on the basis of one (1) rights share for every two (2) existing Shares held on the record date on a non-underwritten basis, as announced by the Company on 24 June 2026 (the “**Rights Issue**”); and (ii) the proposed issue of convertible bonds in the aggregate principal amount of HK\$50,000,000 under specific mandate, as announced by the Company on 27 May 2026 (the “**Convertible Bonds**”), as at the date of this announcement, the Company does not have any intention or any immediate plan to conduct equity fundraising by issuing new Shares from any part of the increased authorised share capital. However, the Board cannot rule out the possibility that the Company will conduct debt fundraising and/or equity fundraising exercises as and when suitable fundraising opportunities arise in order to support the operations and future development of the Group. The Company will make further announcement in this regard as and when appropriate in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Increase in Authorised Share Capital is subject to the approval of the Shareholders by way of an ordinary resolution at the extraordinary general meeting of the Company (the “**EGM**”), which will be convened and held for the Shareholders to consider and, if thought fit, approve the Increase in Authorised Share Capital. A circular containing, among other things, further details of the Increase in Authorised Share Capital and the notice convening the EGM is expected to be despatched to the Shareholders on Wednesday, 5 August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By Order of the Board
Biosysen Limited
Lee Tsz Yan
Executive Director

Hong Kong, 5 August 2026

As at the date of this announcement, the Board comprises Ms. Lee Tsz Yan as executive Director; Mr. Cheung Ching Mo and Mr. Hu Xinglong as non-executive Directors; and Mr. Wu Jilin, Mr. Lam Cheung Shing Richard and Mr. So Yin Wai as independent non-executive Directors.